Antonio Jose Sanchez

List of Publications by Year
in descending order

40 papers	1,349 citations	394421 19 h-index	345221 36 g-index
43 all docs	43 docs citations	43 times ranked	2291 citing authors

#	Article	IF	Citations
1	Effect of Expanded Hemodialysis with Theranova® in Patients with COVID-19. Blood Purification, 2022, 51, 857-865.	1.8	2
2	Exploring the potential relationship between collagen cross-linking and impaired myocardial relaxation in Marfan syndrome: An observational study using serum biomarkers. International Journal of Cardiology, 2022, , .	1.7	1
3	Polymorphisms in ACE, ACE2, AGTR1 genes and severity of COVID-19 disease. PLoS ONE, 2022, 17, e0263140.	2.5	38
4	CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	15
5	Nox1-derived oxidative stress as a common pathogenic link between obesity and hyperoxaluria-related kidney injury. Urolithiasis, 2020, 48, 481-492.	2.0	6
6	Serum β-endorphin levels are associated with addiction to suicidal behavior: A pilot study. European Neuropsychopharmacology, 2020, 40, 38-51.	0.7	4
7	Serum endocannabinoid levels in suicide attempters: A pilot study. European Neuropsychopharmacology, 2020, 40, 52-60.	0.7	12
8	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain, 2018, 141, 1085-1093.	7.6	115
9	Cannabinoid Receptors, Mental Pain and Suicidal Behavior: a Systematic Review. Current Psychiatry Reports, 2018, 20, 19.	4.5	11
10	Metabolic syndrome contributes to renal injury mediated by hyperoxaluria in a murine model of nephrolithiasis. Urolithiasis, 2018, 46, 179-186.	2.0	9
11	Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course. Journal of Neuroinflammation, 2018, 15, 265.	7.2	25
12	Immunophenotype and Transcriptome Profile of Patients With Multiple Sclerosis Treated With Fingolimod: Setting Up a Model for Prediction of Response in a 2-Year Translational Study. Frontiers in Immunology, 2018, 9, 1693.	4.8	32
13	Mechanisms of action of cannabidiol in adoptively transferred experimental autoimmune encephalomyelitis. Experimental Neurology, 2017, 298, 57-67.	4.1	28
14	Spontaneous Cannabinoid Receptor 2 (CB2) Expression in the Cochlea of Adult Albino Rat and Its Up-Regulation after Cisplatin Treatment. PLoS ONE, 2016, 11, e0161954.	2.5	26
15	Pharmacogenomic study in patients with multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e154.	6.0	19
16	Cannabinoids receptor type 2, CB2, expression correlates with human colon cancer progression and predicts patient survival. Oncoscience, 2015, 2, 131-141.	2.2	57
17	Influence of the LILRA3 Deletion on Multiple Sclerosis Risk: Original Data and Meta-Analysis. PLoS ONE, 2015, 10, e0134414.	2.5	5
18	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain, 2015, 138, 918-931.	7.6	147

#	Article	IF	Citations
19	Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis. Expert Review of Neurotherapeutics, 2014, 14, 1243-1250.	2.8	13
20	The cannabinoid system in human mesenchymal cells. Journal of Neuroimmunology, 2014, 275, 189-190.	2.3	0
21	Therapeutic potential of human mesenchymal cells from Multiple Sclerosis patients in EAE. Journal of Neuroimmunology, 2014, 275, 190.	2.3	1
22	Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon-β: a longitudinal study in multiple sclerosis patients. Clinical and Experimental Immunology, 2014, 179, 119-127.	2.6	38
23	Neuroprotective agents: Cannabinoids. Clinical Immunology, 2012, 142, 57-67.	3.2	95
24	Esclerosis múltiple. Factores etiológicos, modelos experimentales, mecanismos patogénicos e inmunopatología. Medicine, 2011, 10, 5069-5078.	0.0	0
25	Manifestaciones clínicas, historia natural, pronóstico y complicaciones de la esclerosis múltiple. Medicine, 2011, 10, 5079-5086.	0.0	0
26	Tratamiento de la esclerosis múltiple. Medicine, 2011, 10, 5094-5100.	0.0	0
27	Otras enfermedades desmielinizantes. Medicine, 2011, 10, 5101-5107.	0.0	0
28	Protocolo diagnóstico del paciente con sospecha de enfermedad desmielinizante. Medicine, 2011, 10, 5109-5111.	0.0	0
29	Protocolo terapéutico de la esclerosis múltiple. Medicine, 2011, 10, 5112-5113.	0.0	0
30	IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis. Journal of Neuroimmunology, 2011, 239, 101-104.	2.3	18
31	ISNI 2010 Abstracts. Journal of Neuroimmunology, 2010, 228, 1-219.	2.3	4
32	The cannabinoid receptor 1 gene (CNR1) and multiple sclerosis: an association study in two case-control groups from Spain. Multiple Sclerosis Journal, 2010, 16, 139-146.	3.0	25
33	Los estudiantes con discapacidad en la Universidad de Almería: Ideas y Actitudes sobre su integración Educativa y Social. European Journal of Education and Psychology, 2010, 3, 329.	1.5	9
34	Multiple sclerosis associates with LILRA3 deletion in Spanish patients. Genes and Immunity, 2009, 10, 579-585.	4.1	42
35	Selective Induction of cAMP Phosphodiesterase PDE4B2 Expression in Experimental Autoimmune Encephalomyelitis. Journal of Neuropathology and Experimental Neurology, 2007, 66, 923-931.	1.7	32
36	R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: Partial involvement of the CB2 receptor. Biochemical Pharmacology, 2006, 72, 1697-1706.	4.4	53

#	Article	IF	Citations
37	Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiology of Disease, 2005, 20, 207-217.	4.4	131
38	Rolipram impairs NF-ĸB activity and MMP-9 expression in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2005, 168, 13-20.	2.3	27
39	A sustained activation of PI3K/NF-ĸB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia, 2004, 18, 1391-1400.	7.2	233
40	Changes in cannabinoid CB1receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse, 2001, 41, 195-202.	1.2	62